As pharmaceutical consultants, the scientists and regulatory professionals at PDG® design pharmacokinetic (PK) protocols for a wide variety of applications. This paper has been written to provide the reader with a basic review of pharmacokinetic and pharmacodynamics (PD) principles as well as an exposure to a cross section of the utility of PK studies. Click here to access the paper.
Pharmaceutical Development Group (PDG) is a subsidiary of Biotech Research Group Corporation.
PDG
Pharmaceutical Development Group
- Home
- Services
- Pharmaceutical Consulting Services
- Strategic Drug Development
- Strategic Drug Development Services
- Pharmaceutical Development Programs: Implementation and Oversight
- Pre-IND Meetings
- Investigational New Drug Application (IND)/Special Protocol Assessment (SPA)
- Clinical Trial Design
- Pre-NDA Meetings and NDA Submissions: 505(b)(1)/505(b)(2)
- 505(b)(2) NDAs
- Generic Drugs: 505(j) ANDAs and Potential Diversification
- Nonprescription Drugs (OTC)
- Medical Device Consulting
- Post-Launch Activities
- Specialty Services
- Regulatory Updates
- About PDG
- Regulatory Resources
- Contact PDG
- Home
- Services
- Pharmaceutical Consulting Services
- Strategic Drug Development
- Strategic Drug Development Services
- Pharmaceutical Development Programs: Implementation and Oversight
- Pre-IND Meetings
- Investigational New Drug Application (IND)/Special Protocol Assessment (SPA)
- Clinical Trial Design
- Pre-NDA Meetings and NDA Submissions: 505(b)(1)/505(b)(2)
- 505(b)(2) NDAs
- Generic Drugs: 505(j) ANDAs and Potential Diversification
- Nonprescription Drugs (OTC)
- Medical Device Consulting
- Post-Launch Activities
- Specialty Services
- Regulatory Updates
- About PDG
- Regulatory Resources
- Contact PDG
Download Our Latest Paper: A drug development overview of pharmacokinetic principles related to ANDA/505(b)(2) submissions
You are here:
- Home
- Breaking News
- Download Our Latest Paper: A…